Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2017 Jun 6;116(12):1520-1525.
doi: 10.1038/bjc.2017.103. Epub 2017 Apr 27.

Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study

Luca Triggiani  1 , Filippo Alongi  2 , Michela Buglione  1 , Beatrice Detti  3 , Riccardo Santoni  4 , Alessio Bruni  5 , Ernesto Maranzano  6 , Frank Lohr  5 , Rolando D'Angelillo  7 , Alessandro Magli  8 , Alberto Bonetta  9 , Rosario Mazzola  2 , Nadia Pasinetti  1 , Giulio Francolini  3 , Gianluca Ingrosso  4 , Fabio Trippa  6 , Sergio Fersino  2 , Paolo Borghetti  1 , Paolo Ghirardelli  1 , Stefano Maria Magrini  1
Affiliations
Multicenter Study

Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study

Luca Triggiani et al. Br J Cancer. .

Abstract

Background: The aim of the present study is to evaluate the impact of metastases-directed stereotactic body radiotherapy in two groups of oligometastatic prostate cancer (PC) patients: oligorecurrent PC and oligoprogressive castration-resistant PC (oligo-CRPC).

Methods: Inclusion criteria of the present multicentre retrospective analysis were: (1) oligorecurrent PC, defined as the presence of 1-3 lesions (bone or nodes) detected with choline positron emission tomography or CT plus bone scan following biochemical recurrence; (2) oligo-CRPC, defined as metastases (bone or nodes) detected after a prostatic-specific antigen rise during androgen deprivation therapy (ADT). Primary end points were: distant progression-free survival (DPFS) and ADT-free survival in oligorecurrent PC patients; DPFS and second-line systemic treatment-free survival in oligo-CRPC patients.

Results: About 100 patients with oligorecurrent PC (139 lesions) and 41 with oligo-CRPC (70 lesions), treated between March 2010 and April 2016, were analysed. After a median follow-up of 20.4 months, in the oligorecurrent group 1- and 2-year DPFS were 64.4 and 43%. The rate of LC was 92.8% at 2 years. At a median follow-up of 23.4 months, in the oligo-CRPC group 1- and 2-year DPFS were 43.2 and 21.6%. Limitations include the retrospective design.

Conclusions: Stereotactic body radiotherapy seems to be a useful treatment both for oligorecurrent and oligo-CRPC.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Sites of oligorecurrences underwent to stereotactic body radiotherapy in the current study. Sites of oligorecurrence: obturator lymph nodes (Ob N)=28 (20.1%); internal iliac lymph nodes (II N)=18 (12.9%); external iliac lymph nodes (EI N)=21 (15.1%); presacral/common iliac lymph nodes (S/CI N)=16 (11.5%); paraortic lymph nodes (PA N)=34 (24.4%); bone=22 (15.8%). A full colour version of this figure is available at the British Journal of Cancer journal online.
See this image and copyright information in PMC

Comment in

References

    1. Ahmed KA, Barney BM, Davis BJ, Park SS, Kwon ED, Olivier KR (2013) Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer. Front Oncol 2: 215. - PMC - PubMed
    1. Alongi F, Arcangeli S, Filippi AR, Ricardi U, Scorsetti M (2012) Review and uses of stereotactic body radiation therapy for oligometastases. Oncologist 17(8): 1100–1107. - PMC - PubMed
    1. Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, Fizazi K, Joshua AM, Kim CS, Kimura G, Mainwaring P, Mansbach H, Miller K, Noonberg SB, Perabo F, Phung D, Saad F, Scher HI, Taplin ME, Venner PM, Tombal B (2014) Enzalutamide in metastatic prostate cancer before chemotherapy; PREVAIL Investigators. N Engl J Med 371: 424–433. - PMC - PubMed
    1. Casamassima F, Masi L, Menichelli C, Bonucci I, Casamassima E, Lazzeri M, Gulisano M, Aterini S (2011) Efficacy of eradicative radiotherapy for limited nodal metastases detected with choline PET scan in prostate cancer patients. Tumori 97(1): 49–55. - PubMed
    1. Cheng HH, Lin DW, Yu EY (2012) Advanced clinical states in prostate cancer. Urol Clin North Am 39: 561–571. - PubMed

Publication types

MeSH terms

Substances